Karyopharm Therapeutics (KPTI) Competitors

$0.60 +0.01 (+0.83%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.60 0.00 (0.00%)

As of 10/9/2026 07:57 PM Eastern

KPTI vs. ALDX, SPRO, CING, FBIO, and HRTX

Should you buy Karyopharm Therapeutics stock or one of its competitors? Karyopharm Therapeutics's main competitors and comparable companies include Aldeyra Therapeutics (ALDX), Spero Therapeutics (SPRO), Cingulate (CING), Fortress Biotech (FBIO), and Heron Therapeutics (HRTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Karyopharm Therapeutics compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 500.24%. Karyopharm Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 1,800.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

Aldeyra Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Aldeyra Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Karyopharm Therapeutics	$146.07M	0.09	-$196.04M	-$13.09	N/A

In the previous week, Aldeyra Therapeutics and Aldeyra Therapeutics both had 1 articles in the media. Aldeyra Therapeutics' average media sentiment score of -0.29 beat Karyopharm Therapeutics' score of -0.33 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Neutral
Karyopharm Therapeutics	Neutral

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Karyopharm Therapeutics beats Aldeyra Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Spero Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 2.9% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Karyopharm Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Karyopharm Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 1,800.83%. Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 400.00%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Spero Therapeutics has a net margin of 24.90% compared to Karyopharm Therapeutics' net margin of -153.28%. Spero Therapeutics' return on equity of 16.17% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Spero Therapeutics	24.90%	16.17%	12.57%

Spero Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.09	-$196.04M	-$13.09	N/A
Spero Therapeutics	$66.80M	1.05	$8.57M	$0.11	10.91

In the previous week, Spero Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for Karyopharm Therapeutics. Spero Therapeutics' average media sentiment score of 0.42 beat Karyopharm Therapeutics' score of -0.33 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Spero Therapeutics	Neutral

Summary

Spero Therapeutics beats Karyopharm Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Cingulate?

Cingulate (NASDAQ:CING) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

41.3% of Cingulate shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 5.3% of Cingulate shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cingulate has a beta of -0.88, meaning that its share price is 188% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Cingulate has higher earnings, but lower revenue than Karyopharm Therapeutics. Cingulate is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A
Karyopharm Therapeutics	$146.07M	0.09	-$196.04M	-$13.09	N/A

Cingulate currently has a consensus target price of $27.00, suggesting a potential upside of 452.15%. Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 1,800.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Cingulate has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-238.40%	-128.67%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

In the previous week, Cingulate and Cingulate both had 1 articles in the media. Cingulate's average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.33 indicating that Cingulate is being referred to more favorably in the media.

Company	Overall Sentiment
Cingulate	Neutral
Karyopharm Therapeutics	Neutral

Summary

Karyopharm Therapeutics beats Cingulate on 8 of the 14 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Fortress Biotech and Fortress Biotech both had 1 articles in the media. Fortress Biotech's average media sentiment score of -0.03 beat Karyopharm Therapeutics' score of -0.33 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Fortress Biotech	Neutral
Karyopharm Therapeutics	Neutral

Fortress Biotech has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.12	$6.82M	$2.64	0.81
Karyopharm Therapeutics	$146.07M	0.09	-$196.04M	-$13.09	N/A

Fortress Biotech has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Fortress Biotech has a net margin of 163.32% compared to Karyopharm Therapeutics' net margin of -153.28%. Fortress Biotech's return on equity of 83.47% beat Karyopharm Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Fortress Biotech presently has a consensus price target of $17.00, suggesting a potential upside of 698.12%. Karyopharm Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 1,800.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

Fortress Biotech beats Karyopharm Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Heron Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for Heron Therapeutics and 1 mentions for Karyopharm Therapeutics. Heron Therapeutics' average media sentiment score of 0.24 beat Karyopharm Therapeutics' score of -0.33 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Neutral
Karyopharm Therapeutics	Neutral

Heron Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Heron Therapeutics currently has a consensus target price of $2.00, suggesting a potential upside of 392.49%. Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 1,800.83%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Heron Therapeutics has higher revenue and earnings than Karyopharm Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$151.18M	0.51	-$20.19M	-$0.19	N/A
Karyopharm Therapeutics	$146.07M	0.09	-$196.04M	-$13.09	N/A

Heron Therapeutics has a net margin of -22.52% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-22.52%	-293.02%	-10.00%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Summary

Heron Therapeutics beats Karyopharm Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.61M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.05	797.58	274.15	26.16
Price / Sales	0.09	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	-0.04	10.71	11.21	6.34
Net Income	-$196.04M	$2.84B	$3.50B	$381.90M
7 Day Performance	-24.58%	-0.93%	-0.90%	-1.41%
1 Month Performance	-62.65%	-4.91%	-4.44%	-3.48%
1 Year Performance	-89.00%	-4.13%	6.96%	1.16%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	3.256 of 5 stars	$0.61 +0.8%	$11.50 +1,800.8%	-89.6%	$13.61M	$146.07M	N/A	228
ALDX Aldeyra Therapeutics	2.5519 of 5 stars	$0.92 -21.1%	$5.50 +495.4%	-83.8%	$70.58M	N/A	N/A	6	High Trading Volume
SPRO Spero Therapeutics	3.689 of 5 stars	$1.16 -2.5%	$6.00 +417.2%	-49.2%	$69.30M	$42.96M	10.55	25
CING Cingulate	1.9198 of 5 stars	$4.75 -0.2%	$27.00 +468.4%	+12.4%	$69.22M	N/A	N/A	14
FBIO Fortress Biotech	2.3468 of 5 stars	$2.09 +3.0%	$17.00 +713.4%	-23.9%	$67.70M	$63.26M	0.79	78	News Coverage Analyst Upgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ALDX, SPRO, CING, FBIO, and HRTX

How does Karyopharm Therapeutics compare to Aldeyra Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Spero Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Cingulate?

Summary

How does Karyopharm Therapeutics compare to Fortress Biotech?

Summary

How does Karyopharm Therapeutics compare to Heron Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. ALDX, SPRO, CING, FBIO, and HRTX

How does Karyopharm Therapeutics compare to Aldeyra Therapeutics?

Do analysts prefer ALDX or KPTI?

Which has more volatility & risk, ALDX or KPTI?

Is ALDX or KPTI more profitable?

Which has preferable valuation and earnings, ALDX or KPTI?

Does the media prefer ALDX or KPTI?

Do insiders & institutionals hold more shares of ALDX or KPTI?

Summary

How does Karyopharm Therapeutics compare to Spero Therapeutics?

Do institutionals and insiders hold more shares of KPTI or SPRO?

Which has more volatility & risk, KPTI or SPRO?

Do analysts recommend KPTI or SPRO?

Is KPTI or SPRO more profitable?

Which has better valuation and earnings, KPTI or SPRO?

Does the media favor KPTI or SPRO?

Summary

How does Karyopharm Therapeutics compare to Cingulate?

Do institutionals and insiders hold more shares of CING or KPTI?

Which has more risk & volatility, CING or KPTI?

Which has better valuation & earnings, CING or KPTI?

Do analysts recommend CING or KPTI?

Is CING or KPTI more profitable?

Does the media prefer CING or KPTI?

Summary

How does Karyopharm Therapeutics compare to Fortress Biotech?

Does the media prefer FBIO or KPTI?

Which has higher earnings and valuation, FBIO or KPTI?

Which has more volatility & risk, FBIO or KPTI?

Do institutionals & insiders hold more shares of FBIO or KPTI?

Is FBIO or KPTI more profitable?

Do analysts recommend FBIO or KPTI?

Summary

How does Karyopharm Therapeutics compare to Heron Therapeutics?

Do insiders & institutionals hold more shares of HRTX or KPTI?

Does the media prefer HRTX or KPTI?

Which has more risk and volatility, HRTX or KPTI?

Do analysts recommend HRTX or KPTI?

Which has stronger valuation and earnings, HRTX or KPTI?

Is HRTX or KPTI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools